PCM
PRVL

Penserra Capital Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Penserra Capital Management’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-785
Closed -$18K – 1160
2020
Q4 		$18K Buy
785
+493
+169% +$6.25K ﹤0.01% 866
2020
Q3 		$2K Buy
+292
New +$3.92K ﹤0.01% 916

Penserra Capital Management's PRVL Position: Q1 2021 in Review

Penserra Capital Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 785 shares — an estimated $18K sold.

Penserra Capital Management first reported a position in PRVL in Q3 2020 and held it in 2 quarters. The position peaked at $18K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Penserra Capital Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Penserra Capital Management sold 785 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $18K.
  • Penserra Capital Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Penserra Capital Management's Prevail Therapeutics Inc. Common Stock position peaked at $18K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Penserra Capital Management's 13F filing for Q1 2021, filed 13 May 2021.